HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,912,000 | -42.3% | 45,855 | -40.9% | 0.01% | -39.1% |
| Q4 2020 | $3,314,000 | +41.3% | 77,578 | -13.1% | 0.02% | +43.8% |
| Q3 2020 | $2,346,000 | -23.2% | 89,278 | -21.6% | 0.02% | -33.3% |
| Q2 2020 | $3,053,000 | +53.7% | 113,878 | +3.2% | 0.02% | +33.3% |
| Q1 2020 | $1,986,000 | -11.2% | 110,378 | -12.5% | 0.02% | +20.0% |
| Q4 2019 | $2,236,000 | -7.8% | 126,078 | -19.4% | 0.02% | 0.0% |
| Q3 2019 | $2,425,000 | -22.8% | 156,378 | -14.4% | 0.02% | -28.6% |
| Q2 2019 | $3,140,000 | +258.9% | 182,778 | +236.3% | 0.02% | +250.0% |
| Q1 2019 | $875,000 | +15.7% | 54,355 | +5.2% | 0.01% | 0.0% |
| Q4 2018 | $756,000 | -35.9% | 51,655 | -20.4% | 0.01% | -33.3% |
| Q3 2018 | $1,179,000 | +60.0% | 64,863 | +48.6% | 0.01% | +80.0% |
| Q2 2018 | $737,000 | -16.2% | 43,663 | -2.7% | 0.01% | 0.0% |
| Q1 2018 | $879,000 | – | 44,863 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |